Form 8-K IONIS PHARMACEUTICALS For: Jun 04

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  June 4, 2026

 

IONIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

2855 Gazelle Court

Carlsbad, CA 92010

(Address of Principal Executive Offices and Zip Code)

 

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

 

 

On June 4, 2026, the Board of Directors (“Board”) of Ionis Pharmaceuticals, Inc. (the “Company”) appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders.

Dr. Hantson has more than 30 years of leadership experience at biopharmaceutical and medical device companies. He served as chief executive officer and board member of Alexion from 2017-2021, prior to its acquisition by AstraZeneca.  Before joining Alexion, Dr. Hantson served as president of Baxter Bioscience, where he led the spin-off of Baxalta, serving as chief executive officer and board member. Earlier in his career, he held senior leadership roles at Novartis across North America and Europe, including chief executive officer of North America, and spent 13 years at Johnson & Johnson in roles of increasing responsibility. In addition to serving as a director at Alexion and Baxalta, Dr. Hantson served as a director at Hologic, a medical device innovator. He holds a master’s degree in physical education and a Ph.D. in motor rehabilitation & physical therapy from the University of Louvain in Belgium.

There are no arrangements or understandings between Dr. Hantson and any other persons pursuant to which Dr. Hantson was appointed as a director of the Company.

Dr. Hantson will receive the standard compensation that the Company provides to its non-employee directors, which consists of cash compensation and automatic equity grants as set forth in the Company’s Fourth Amended Non-Employee Director Compensation Policy, filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed on April 29, 2026, as amended from time to time.

In addition, Dr. Hantson will enter into the Company’s standard form of indemnity agreement.

As previously announced in the Form 8-K filed with the SEC on March 9, 2026, the Company also appointed Peter N. Reikes as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders.

On June 8, 2026, the Company issued a press release announcing that Dr. Hantson was appointed to the Company’s Board on June 4, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

The Company held its virtual Annual Meeting of Stockholders on June 4, 2026.  The stockholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 23, 2026.

The Company’s stockholders elected the foregoing candidates by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of directors.

 

“RESOLVED, that Ionis’ stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.”

 

The Company’s stockholders approved the foregoing proposal.

 

 

The Company’s stockholders approved the foregoing proposal.

 

 

The Company’s stockholders approved the foregoing proposal.

 

The Company’s stockholders approved the foregoing proposal.

(d) Exhibits.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Ionis Pharmaceuticals, Inc.
Dated:  June 8, 2026	By:	/s/ Patrick R. O’Neil
		Patrick R. O’Neil
		Executive Vice President, Legal, General Counsel and Chief Compliance Officer